Wednesday, August 6, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Tafasitamab Combo Approved for r/r Follicular Lymphoma

June 19, 2025
in Health News
Share on FacebookShare on Twitter


The US Food and Drug Administration has approved tafasitamab (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory (r/r) follicular lymphoma (FL).

Lenalidomide with rituximab (R2) is already a common, chemotherapy-free option for FL in the first, and especially second, lines. Adding tafasitamab, an anti-CD19 immunotherapy, improved progression-free survival (PFS) from 14.1 to 22.4 months in inMIND, Incyte’s approval trial. 

The triple-agent regimen “may redefine the standard for relapsed patients, especially those not yet eligible for bispecifics or CAR-T, or for use after those therapies,” Khushali Jhaveri, MD, lymphoma specialist at Indiana University in Indianapolis, said in a recent Medscape Oncology commentary. “However,” she cautioned, “whether tafasitamab induces CD19 loss — and potentially affects eligibility for future CAR-T — remains an important open question.” 

Tafasitamab was previously approved with lenalidomide for r/r diffuse large B-cell lymphoma not otherwise specified and ineligible for autologous stem cell transplant.

The inMIND trial randomized 548 patients with grade 1-3a r/r FL to tafasitamab or placebo with R2. Patients had a median of one prior line of systemic therapy; 25% and 20% had two, three, or more prior lines, respectively.

Incyte noted in a press release that the PFS benefit with tafasitamab add-on (hazard ratio, 0.43, P < .0001) held regardless of the number of prior treatment lines patients had. 

A third of tafasitamab patients in inMIND had serious adverse events, including serious infections in 24%. Other serious reactions included renal insufficiency (3.3%), second primary malignancies (2.9%), and febrile neutropenia (2.6%); 1.5% of patients died of adverse events.

The most common clinical adverse events were respiratory tract infections, diarrhea, rash, fatigue, constipation, musculoskeletal pain, and cough. The most common grade 3/4 laboratory abnormalities were decreased neutrophils and lymphocytes.

The recommended dose of tafasitamab with lenalidomide and rituximab is 12 mg/kg IV for a maximum of 12 cycles. Powder for one 200-mg injection costs $1500.12, according to drugs.com. Incyte offers financial assistance to eligible patients. Information is available at www.incytecares.com.

Jhaveri had no relevant financial disclosures. 

M. Alexander Otto is a physician assistant with a master’s degree in medical science and a journalism degree from Newhouse. He is an award-winning medical journalist who worked for several major news outlets before joining Medscape Medical News. Alex is also an MIT Knight Science Journalism fellow. Email: [email protected].



Source link : https://www.medscape.com/viewarticle/tafasitamab-combo-approved-r-r-follicular-lymphoma-2025a1000gbw?src=rss

Author :

Publish date : 2025-06-19 05:55:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

Shropshire maternity failings investigation to interview staff

Next Post

What to Know About the New COVID Variant

Related Posts

Health News

Can Heart Murmurs Reliably Detect Valvular Disease?

August 6, 2025
Health News

Large Thymus Linked to Atopic Dermatitis Risk in Toddlers

August 6, 2025
Health News

RFK Jr cancels $500m in mRNA vaccine development in the US

August 6, 2025
Health News

Short course of psychotherapy relieves lower back pain for three years

August 5, 2025
Health News

Brain Training Relieves Low Back Pain Long-Term

August 5, 2025
Health News

Heidi Klum’s Worm Cleanse: ‘Medically Unfounded, Potentially Harmful’

August 5, 2025
Load More

Can Heart Murmurs Reliably Detect Valvular Disease?

August 6, 2025

Large Thymus Linked to Atopic Dermatitis Risk in Toddlers

August 6, 2025

RFK Jr cancels $500m in mRNA vaccine development in the US

August 6, 2025

Short course of psychotherapy relieves lower back pain for three years

August 5, 2025

Brain Training Relieves Low Back Pain Long-Term

August 5, 2025

Heidi Klum’s Worm Cleanse: ‘Medically Unfounded, Potentially Harmful’

August 5, 2025

We can repurpose retired coal plants to produce green energy

August 5, 2025

Lorazepam Reduced Restlessness, Agitation in Cancer Patients With Delirium

August 5, 2025
Load More

Categories

Archives

August 2025
MTWTFSS
 123
45678910
11121314151617
18192021222324
25262728293031
« Jul    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version